$RNLXY
Renalytix plc Stock $rnlxy

$rnlxy Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-K Financial Statement

#000095017024110315 Filed on September 30, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2024
Revenue	$522.0K		$2.289M
YoY Change	13.73%		-32.74%
Cost Of Revenue	$422.0K		$2.133M
YoY Change	-15.94%		-20.5%
Gross Profit	$100.0K		$156.0K
YoY Change	-332.56%		-78.33%
Gross Profit Margin	19.16%		6.82%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development	$921.0K		$9.290M
YoY Change	-66.95%		-35.03%
% of Gross Profit	921.0%		5955.13%
Depreciation & Amortization	$60.00K		$364.0K
YoY Change	-52.76%		-28.35%
% of Gross Profit	60.0%		233.33%
Operating Expenses	$4.192M		$29.76M
YoY Change	-52.61%		-30.69%
Operating Profit	-$4.093M		-$29.61M
YoY Change	-53.95%		-29.87%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$5.000K		$249.0K
YoY Change	-105.0%		-53.72%
Pretax Income	-$4.726M		-$33.45M
YoY Change	-53.46%		-26.65%
Income Tax	$2.000K		$4.000K
% Of Pretax Income
Net Earnings	-$4.728M		-$33.46M
YoY Change	-53.44%		-26.64%
Net Earnings / Revenue	-905.75%		-1461.6%
Basic Earnings Per Share	-$0.04		-$0.31
Diluted Earnings Per Share	-$0.04		-$0.31
COMMON SHARES
Basic Shares Outstanding	165.9M	154.4M	108.2M
Diluted Shares Outstanding	105.7M		108.2M

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$900.0K	$4.680M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables	$902.0K	$722.0K
Other Receivables
Total Short-Term Assets	$2.879M	$6.118M
YoY Change	-82.52%	-77.24%
LONG-TERM ASSETS
Property, Plant & Equipment	$202.0K	$216.0K
YoY Change	-78.6%	-78.97%
Goodwill
YoY Change
Intangibles	$869.0K	$869.0K
YoY Change	-10.78%	-17.24%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.915M	$1.854M
YoY Change	-37.6%	-50.52%
TOTAL ASSETS
Total Short-Term Assets	$2.879M	$6.118M
Total Long-Term Assets	$1.915M	$1.854M
Total Assets	$4.794M	$7.972M
YoY Change	-75.47%	-73.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$2.162M	$3.354M
YoY Change	-52.65%	-49.52%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$12.01M	$11.50M
YoY Change	-20.83%	-28.76%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.01M	$11.50M
Total Long-Term Liabilities
Total Liabilities	$16.11M	$15.83M
YoY Change	-23.38%	-33.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$216.5M	-$211.8M
YoY Change	14.85%	18.79%
Common Stock	$207.2M	$205.4M
YoY Change	10.04%	9.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$11.32M	-$7.854M
YoY Change
Total Liabilities & Shareholders Equity	$4.794M	$7.972M
YoY Change	-75.47%	-73.97%

Cashflow Statement

Concept	2024 Q3	2024
OPERATING ACTIVITIES
Net Income	-$4.728M	-$33.46M
YoY Change	-53.44%	-26.64%
Depreciation, Depletion And Amortization	$60.00K	$364.0K
YoY Change	-52.76%	-28.35%
Cash From Operating Activities	-$3.836M	-$30.11M
YoY Change	-59.64%	-11.66%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$23.00K	-$4.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$13.53M
YoY Change		-33.32%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	10.25M
YoY Change	-100.0%	-37.45%
NET CHANGE
Cash From Operating Activities	-3.836M	-30.11M
Cash From Investing Activities	23.00K	-4.000K
Cash From Financing Activities	0.000	10.25M
Net Change In Cash	-3.771M	-20.00M
YoY Change	-65.05%	20.12%
FREE CASH FLOW
Cash From Operating Activities	-$3.836M	-$30.11M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001811115
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	00-0000000
CY2024	dei	No Trading Symbol Flag NoTradingSymbolFlag	true
CY2023Q4	dei	Entity Public Float EntityPublicFloat	24705142
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#LiabilitiesCurrent
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OperatingLeaseLiabilityNoncurrent
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-39387
CY2024	dei	Entity Registrant Name EntityRegistrantName	Renalytix plc
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	2 Leman Street
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2024	dei	Entity Address Country EntityAddressCountry	GB
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	E1W 9US
CY2024	dei	City Area Code CityAreaCode	20
CY2024	dei	Local Phone Number LocalPhoneNumber	3139 2910
CY2024	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.0025 per share
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2024	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	165925513
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024	dei	Auditor Name AuditorName	CohnReznick
CY2024	dei	Auditor Location AuditorLocation	Iselin, New Jersey
CY2024	dei	Auditor Firm AuditorFirmId	42
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4680000
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	24682000
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	722000
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	776000
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	716000
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1424000
CY2024Q2	us-gaap	Assets Current AssetsCurrent	6118000
CY2023Q2	us-gaap	Assets Current AssetsCurrent	26882000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	216000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	159000
CY2024Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	698000
CY2023Q2	us-gaap	Investment Owned At Fair Value InvestmentOwnedAtFairValue	1460000
CY2024Q2	us-gaap	Other Assets OtherAssets	940000
CY2023Q2	us-gaap	Other Assets OtherAssets	1101000
CY2024Q2	us-gaap	Assets Assets	7972000
CY2023Q2	us-gaap	Assets Assets	30629000
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3354000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6644000
CY2024Q2	rnlx	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	1329000
CY2023Q2	rnlx	Accrued Expenses Related Party Current AccruedExpensesRelatedPartyCurrent	1963000
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45000
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	130000
CY2024Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4159000
CY2023Q2	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	4463000
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	11495000
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	16136000
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	4331000
CY2023Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	7485000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	41000
CY2024Q2	us-gaap	Liabilities Liabilities	15826000
CY2023Q2	us-gaap	Liabilities Liabilities	23662000
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0025
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0025
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	161842057
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	161842057
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	154368191
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	154368191
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	93781478
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	93781478
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	478000
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	286000
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	204893000
CY2023Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	186456000
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1443000
CY2023Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1450000
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211782000
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-178325000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-7854000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6967000
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	7972000
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30629000
CY2024	us-gaap	Revenues Revenues	2289000
CY2023	us-gaap	Revenues Revenues	3403000
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	2133000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2683000
CY2024	us-gaap	Gross Profit GrossProfit	156000
CY2023	us-gaap	Gross Profit GrossProfit	720000
CY2024	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	9290000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	14298000
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19751000
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28662000
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	723000
CY2024	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	0
CY2023	rnlx	Performance Of Contract Liability To Affiliate PerformanceOfContractLiabilityToAffiliate	19000
CY2024	us-gaap	Operating Expenses OperatingExpenses	29764000
CY2023	us-gaap	Operating Expenses OperatingExpenses	42941000
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-29608000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-42221000
CY2024	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9000
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	163000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	358000
CY2024	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	505000
CY2023	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	1282000
CY2024	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	3751000
CY2023	rnlx	Fair Value Adjustment To Convertible Notes FairValueAdjustmentToConvertibleNotes	3107000
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	249000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	656000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33452000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-45605000
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-33456000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-45607000
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.31
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.31
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108179366
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	82210050
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108179366
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	82210050
CY2024	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	305000
CY2023	rnlx	Changes In Fair Value Of Convertible Notes ChangesInFairValueOfConvertibleNotes	-337000
CY2024	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-298000
CY2023	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-198000
CY2024	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	33449000
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	46142000
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	30607000
CY2023	rnlx	Stock Issued During Period Value Securities Purchase Agreement StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement	19305000
CY2023	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	261000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2936000
CY2023	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	-337000
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-198000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-45607000
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6967000
CY2024	rnlx	Stock Issued During Period Value Securities Purchase Agreement Net Of Offering Costs StockIssuedDuringPeriodValueSecuritiesPurchaseAgreementNetOfOfferingCosts	11817000
CY2024	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5008000
CY2024	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	1000
CY2024	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	93000
CY2024	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1710000
CY2024	rnlx	Changes In The Fair Value Of The Convertible Notes ChangesInTheFairValueOfTheConvertibleNotes	305000
CY2024	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-298000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-33456000
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-7854000
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-33456000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-45607000
CY2024	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	364000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	508000
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	723000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1710000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	2932000
CY2024	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	0
CY2023	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-9000
CY2024	rnlx	Reversal Of Kantaro Liability ReversalOfKantaroLiability	0
CY2023	rnlx	Reversal Of Kantaro Liability ReversalOfKantaroLiability	55000
CY2024	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	505000
CY2023	rnlx	Fair Value Adjustment To Vericidx Investment FairValueAdjustmentToVericidxInvestment	1282000
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	0
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	1008000
CY2024	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	-135000
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	0
CY2024	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	132000
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0
CY2024	rnlx	Fair Value Adjustments To Convertible Debt FairValueAdjustmentsToConvertibleDebt	3502000
CY2023	rnlx	Fair Value Adjustments To Convertible Debt FairValueAdjustmentsToConvertibleDebt	1999000
CY2024	rnlx	Non Cash Lease Expense NonCashLeaseExpense	67000
CY2023	rnlx	Non Cash Lease Expense NonCashLeaseExpense	106000
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-54000
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-125000
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-798000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1299000
CY2024	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	0
CY2023	us-gaap	Increase Decrease In Due From Affiliates Current IncreaseDecreaseInDueFromAffiliatesCurrent	-75000
CY2024	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	106000
CY2023	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	80000
CY2024	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-433000
CY2023	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	368000
CY2024	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3419000
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3397000
CY2024	rnlx	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	-635000
CY2023	rnlx	Increase Decrease In Accrued Expenses Related Party IncreaseDecreaseInAccruedExpensesRelatedParty	451000
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-46000
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-30111000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34085000
CY2024	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	4000
CY2023	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	0
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	0
CY2024	rnlx	Payment Of Convertible Notes Principal PaymentOfConvertibleNotesPrincipal	1660000
CY2023	rnlx	Payment Of Convertible Notes Principal PaymentOfConvertibleNotesPrincipal	3180000
CY2024	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	13533000
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20296000
CY2024	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	1716000
CY2023	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	991000
CY2024	rnlx	Proceeds From The Issuance Of Ordinary Shares Under Employee Share Purchase Plan ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan	93000
CY2023	rnlx	Proceeds From The Issuance Of Ordinary Shares Under Employee Share Purchase Plan ProceedsFromTheIssuanceOfOrdinarySharesUnderEmployeeSharePurchasePlan	261000
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10250000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16386000
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-137000
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1048000
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20002000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16651000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24682000
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	41333000
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4680000
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	24682000
CY2024	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	0
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	265000
CY2024	us-gaap	Interest Paid Net InterestPaidNet	249000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	0
CY2024	rnlx	Issuance Of Shares For Debt Repayment IssuanceOfSharesForDebtRepayment	-5008000
CY2023	rnlx	Issuance Of Shares For Debt Repayment IssuanceOfSharesForDebtRepayment	0
CY2024	us-gaap	Nature Of Operations NatureOfOperations	<p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1. Business and risks</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Renalytix PLC and its wholly-owned subsidiaries, the “Company” or "Renalytix," is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and significantly lower healthcare costs. KidneyIntelX, the Company’s first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from EHR systems, to generate a unique patient risk score. Additionally, the Company plans to pursue collaborations with pharmaceutical companies and make ‘Pharmaceutical Services Revenue’ a core part of the business going forward with the goal of improving guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception in March 2018, the Company has focused primarily on organizing and staffing the Company, raising capital, developing the KidneyIntelX platform, conducting clinical validation studies for KidneyIntelX, establishing and protecting its intellectual property portfolio and commercial laboratory operations, pursuing regulatory clearance and developing a reimbursement strategy. The Company has funded its operations primarily through equity and debt financings.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks and uncertainties common to early-stage companies in the diagnostics industry, including, but not limited to, ability to secure additional capital to fund operations, compliance with governmental regulations, development by competitors of new technological innovations, dependence on key personnel and protection of proprietary technology. To achieve widespread usage, KidneyIntelX and additional diagnostic products currently under development will require extensive clinical testing and validation prior to regulatory approval and commercialization. These efforts require significant amounts of additional capital, adequate personnel, and infrastructure and extensive compliance-reporting capabilities.</span>
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-211800000
CY2024	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the consolidated financial statements, actual results may materially vary from these estimates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant areas that require management’s estimate include the assumptions used in determining the fair value of share-based awards, determining the fair value of the bonds, recording the prepaid/accrual and associated expense for research and development activities performed for the Company by third parties and determining useful lives of property and equipment and capitalized software.</span></p>
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2024Q2	us-gaap	Cash Cash	4700000
CY2023Q2	us-gaap	Cash Cash	24700000
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	100000
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	700000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	0
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	46000
CY2024	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	0
CY2023	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	0
CY2024	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	0
CY2023	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	46000
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue	0
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	0
CY2023Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	11948000
CY2024	rnlx	Change Due To Payment Of Principal And Interest ChangeDueToPaymentOfPrincipalAndInterest	-6161000
CY2024	rnlx	Fair Value Adjustments FairValueAdjustments	-305000
CY2024	rnlx	Change In Credit Risk Associated With Fair Value ChangeInCreditRiskAssociatedWithFairValue	2972000
CY2024	rnlx	Fair Value Fx Impact FairValueFxImpact	36000
CY2024Q2	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	8490000
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	515000
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1877000
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	299000
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	850000
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	216000
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2024	us-gaap	Depreciation Depreciation	200000
CY2023	us-gaap	Depreciation Depreciation	300000
CY2024Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1527000
CY2023Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	1526000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	658000
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	476000
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	869000
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1050000
CY2024Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	900000
CY2023Q2	us-gaap	Capitalized Computer Software Net CapitalizedComputerSoftwareNet	1100000
CY2024	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	100000
CY2023	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	200000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	181000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	142000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	126000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	126000
CY2024Q2	rnlx	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	294000
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	869000
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1109000
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	442000
CY2024Q2	rnlx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	892000
CY2023Q2	rnlx	Accrued Research And Development Expenses Current AccruedResearchAndDevelopmentExpensesCurrent	1657000
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	388000
CY2023Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3866000
CY2024Q2	rnlx	Accrued License And Royalty Expense AccruedLicenseAndRoyaltyExpense	787000
CY2023Q2	rnlx	Accrued License And Royalty Expense AccruedLicenseAndRoyaltyExpense	669000
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	178000
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	10000
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3354000
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6644000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	21200000
CY2022Q2	rnlx	Senior Convertible Bond Par Value Percentage SeniorConvertibleBondParValuePercentage	0.85
CY2022Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	18000000
CY2022Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.055
CY2022Q2	rnlx	Debt Instrument Convertible Conversion Price Percentage DebtInstrumentConvertibleConversionPricePercentage	0.20
CY2022Q2	rnlx	Debt Instrument Reset Down Term1 DebtInstrumentResetDownTerm1	P12M
CY2022Q2	rnlx	Debt Instrument Reset Down Term2 DebtInstrumentResetDownTerm2	P24M
CY2022Q2	rnlx	Debt Instrument Reset Down Term3 DebtInstrumentResetDownTerm3	P36M
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.25
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.2508
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	6.8757
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.25
CY2023Q1	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.2508
CY2023Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	7.7924
CY2022Q2	rnlx	Repayment Of Deferred Amortization Percentage RepaymentOfDeferredAmortizationPercentage	1
CY2023Q3	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1400000
CY2023Q3	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q3	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	300000
CY2023Q3	rnlx	Acceleratedamountofcashamortizationrepayment Acceleratedamountofcashamortizationrepayment	1100000
CY2023Q4	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1300000
CY2023Q4	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q4	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	200000
CY2023Q4	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1300000
CY2023Q4	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2023Q4	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	200000
CY2023Q4	rnlx	Amortization Payment In Cash AmortizationPaymentInCash	600000
CY2024Q2	rnlx	Amount Of Cash Amortization Payment AmountOfCashAmortizationPayment	1300000
CY2024Q2	rnlx	Principal Of Amount Of Cash Amortization PrincipalOfAmountOfCashAmortization	1100000
CY2024Q2	rnlx	Amount Of Cash Amortization Interest Payment AmountOfCashAmortizationInterestPayment	200000
CY2024	rnlx	Principal Amount Outstanding Of Cash Amortization PrincipalAmountOutstandingOfCashAmortization	12700000
CY2023	rnlx	Principal Amount Outstanding Of Cash Amortization PrincipalAmountOutstandingOfCashAmortization	18000000
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	16900000
CY2024Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	8500000
CY2024	rnlx	Incremental Borrowing Rate Of Average Commercial Real Estate Loans IncrementalBorrowingRateOfAverageCommercialRealEstateLoans	0.10
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	0
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	45000
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	45000
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	353000
CY2024	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	92000
CY2024	us-gaap	Lease Cost LeaseCost	702000
CY2024	us-gaap	Operating Lease Payments OperatingLeasePayments	74000
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y3M18D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	46000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	0
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46000
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1000
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	45000
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	161842057
CY2024	us-gaap	Dividends Cash DividendsCash	0
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5000000
CY2024	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1710000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2936000
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y3M18D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y1M6D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.75
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.669
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.043
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.032
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4968576
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.5
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y8M12D
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3640296
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.04
CY2024	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1133443
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	2.83
CY2024	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1563
CY2024	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	6.64
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	7473866
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.06
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5249671
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.84
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y1M6D
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	7473866
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.06
CY2024	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P7Y
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-12501000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-712000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-20951000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-44894000
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-33452000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-45606000
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.25
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.205
CY2024	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.044
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.104
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.007
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.009
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.284
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.312
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.039
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.011
CY2024	rnlx	Effective Income Tax Rate Reconciliation Deferred Only Percent EffectiveIncomeTaxRateReconciliationDeferredOnlyPercent	-0.043
CY2023	rnlx	Effective Income Tax Rate Reconciliation Deferred Only Percent EffectiveIncomeTaxRateReconciliationDeferredOnlyPercent	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.009
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.001
CY2024	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2024Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	45962000
CY2023Q2	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	37740000
CY2024Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3907000
CY2023Q2	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2826000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2352000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	2814000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2758000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1327000
CY2024Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	46000
CY2023Q2	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	964000
CY2024Q2	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	384000
CY2023Q2	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	256000
CY2024Q2	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	14000
CY2023Q2	us-gaap	Deferred Tax Assets Deferred Gain On Sale Leaseback Transaction DeferredTaxAssetsDeferredGainOnSaleLeasebackTransaction	55000
CY2024Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	97000
CY2023Q2	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	73000
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	55438000
CY2023Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	45602000
CY2024Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	82000
CY2023Q2	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	453000
CY2024Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	66000
CY2023Q2	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	386000
CY2024Q2	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0
CY2023Q2	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	0
CY2024Q2	rnlx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	0
CY2023Q2	rnlx	Deferred Tax Liabilities Right Of Use Assets DeferredTaxLiabilitiesRightOfUseAssets	51000
CY2024Q2	rnlx	Deferred Tax Liabilities Unrealized Currency Losses1 DeferredTaxLiabilitiesUnrealizedCurrencyLosses1	16000
CY2023Q2	rnlx	Deferred Tax Liabilities Unrealized Currency Losses1 DeferredTaxLiabilitiesUnrealizedCurrencyLosses1	16000
CY2024Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	82000
CY2023Q2	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	453000
CY2024Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q2	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2023Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2024	rnlx	Threshold Percentage Set Off Of Annual Profits By Operating Loss Carry Forward ThresholdPercentageSetOffOfAnnualProfitsByOperatingLossCarryForward	0.80
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	9800000
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	14500000
CY2024	rnlx	Net Operating Loss Description NetOperatingLossDescription	In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of 5-percent shareholders in the stock of a corporation by more than 50 percentage points over a three-year period.
CY2024Q2	us-gaap	Finite Lived Intangible Assets Remaining Amortization Period1 FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1	P5Y
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10746515
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10450114

Files In Submission

Name	View Source	Status
0000950170-24-110315-index-headers.html	Edgar Link	pending
0000950170-24-110315-index.html	Edgar Link	pending
0000950170-24-110315.txt	Edgar Link	pending
0000950170-24-110315-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img84508488_0.jpg	Edgar Link	pending
img84508488_1.jpg	Edgar Link	pending
img84508488_2.jpg	Edgar Link	pending
img84508488_3.jpg	Edgar Link	pending
img84508488_4.jpg	Edgar Link	pending
img84508488_5.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rnlx-20240630.htm	Edgar Link	pending
rnlx-20240630.xsd	Edgar Link	pending
rnlx-ex21_1.htm	Edgar Link	pending
rnlx-ex23_1.htm	Edgar Link	pending
rnlx-ex23_2.htm	Edgar Link	pending
rnlx-ex31_1.htm	Edgar Link	pending
rnlx-ex31_2.htm	Edgar Link	pending
rnlx-ex32_1.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rnlx-20240630_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RNLXY
Renalytix plc Stock $rnlxy

2024 Q3 Form 10-K Financial Statement

#000095017024110315 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNLXY Renalytix plc Stock $rnlxy

2024 Q3 Form 10-K Financial Statement

#000095017024110315 Filed on September 30, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RNLXY
Renalytix plc Stock $rnlxy